Detalhe da pesquisa
1.
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Breast Cancer Res Treat
; 174(3): 693-701, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30607629
2.
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Breast Cancer Res Treat
; 177(1): 115-125, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31152327
3.
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Clin Transl Oncol
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578537
4.
Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer.
Breast Cancer Res Treat
; 125(1): 273-8, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20803065
5.
Performance of a Direct Methane Solid Oxide Fuel Cell Using Nickel-Ceria-Yttria Stabilized Zirconia as the Anode.
Materials (Basel)
; 13(3)2020 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32012909
6.
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.
PLoS One
; 12(10): e0184181, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28985233
7.
18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.
Clin Cancer Res
; 23(6): 1432-1441, 2017 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27587436
8.
Critically short telomeres and toxicity of chemotherapy in early breast cancer.
Oncotarget
; 8(13): 21472-21482, 2017 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28423524